Ligand Pharmaceuticals (LGND) Tax Provisions (2010 - 2026)

Ligand Pharmaceuticals has reported Tax Provisions for 17 years, with the latest figure at -$10.9 million in Q1 2026.

• Quarterly Tax Provisions fell 41.21% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.3 million (up 209.95% YoY) and the FY2025 annual result came in at $34.5 million, up 426.82% from the prior year.
• Tax Provisions eased to -$10.9 million in Q1 2026 per LGND's latest filing, from $12.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $38.7 million in Q4 2022 and troughed at -$13.5 million in Q2 2024.
• A 5-year average of $4.8 million and a median of $881000.0 in 2023 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions plunged 1629.97% in 2024, then soared 2764.83% in 2025.
• Over 5 years, Tax Provisions stood at $38.7 million in 2022, then sank by 102.82% to -$1.1 million in 2023, then slumped by 643.54% to -$8.1 million in 2024, then soared by 247.88% to $12.0 million in 2025, then sank by 190.98% to -$10.9 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered -$10.9 million, $12.0 million, and $23.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.